The public float for IBO is 10.07M and currently, short sellers hold a 1.22% of that float. On May 02, 2025, IBO’s average trading volume was 6.16M shares.
IBO) stock’s latest price update
The stock price of Impact BioMedical Inc (AMEX: IBO) has dropped by -6.32 compared to previous close of 0.43. Despite this, the company has seen a fall of -5.88% in its stock price over the last five trading days. globenewswire.com reported 2025-03-21 that HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) — Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material development in its business affairs not previously disclosed or, to its knowledge, any other reason to account for the unusual market action regarding its share price.
IBO’s Market Performance
Impact BioMedical Inc (IBO) has experienced a -5.88% fall in stock performance for the past week, with a -51.22% drop in the past month, and a -78.43% drop in the past quarter. The volatility ratio for the week is 7.08%, and the volatility levels for the past 30 days are at 17.44% for IBO. The simple moving average for the past 20 days is -20.81% for IBO’s stock, with a -77.08% simple moving average for the past 200 days.
IBO Trading at -64.89% from the 50-Day Moving Average
After a stumble in the market that brought IBO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.52% of loss for the given period.
Volatility was left at 17.44%, however, over the last 30 days, the volatility rate increased by 7.08%, as shares sank -29.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -80.00% lower at present.
During the last 5 trading sessions, IBO fell by -5.88%, in comparison to the 20-day moving average, which settled at $0.5051. In addition, Impact BioMedical Inc saw -72.41% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IBO starting from DSS, INC., who sale 890,800 shares at the price of $0.95 back on Apr 04 ’25. After this action, DSS, INC. now owns 161,100 shares of Impact BioMedical Inc, valued at $845,013 using the latest closing price.
Chan Heng Fai Ambrose, the Director of Impact BioMedical Inc, sale 351,555 shares at $0.49 during a trade that took place back on Apr 03 ’25, which means that Chan Heng Fai Ambrose is holding 0 shares at $174,020 based on the most recent closing price.
Stock Fundamentals for IBO
Current profitability levels for the company are sitting at:
- 0.46 for the present operating margin
- 1.0 for the gross margin
The net margin for Impact BioMedical Inc stands at -9.8. The total capital return value is set at 0.09. Equity return is now at value -167.65, with -76.13 for asset returns.
Based on Impact BioMedical Inc (IBO), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -2.49. The debt to equity ratio resting at 0.44. The interest coverage ratio of the stock is 7.34.
Currently, EBITDA for the company is -4.61 million with net debt to EBITDA at -0.22. When we switch over and look at the enterprise to sales, we see a ratio of 7.36. The receivables turnover for the company is 4.64for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.25.
Conclusion
To wrap up, the performance of Impact BioMedical Inc (IBO) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
